2 hours ago
1
TBE/iStock Editorial via Getty Images
Novartis (NYSE:NVS) (OTCPK:NVSEF) has expanded its collaboration with Argo Biopharma, with multi-asset license and option agreements worth up to $5.2B with the Chinese biotech for several cardiovascular assets.
Under the deal announced on Wednesday, the Swiss pharma giant will receive an
English (US) ·